Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 18 · below the Ichimoku cloud · RSI 27 (oversold) · MACD below its signal
| 7.55 | 52-week high | +99.74% |
| 5.49 | Previous month high | +45.11% |
| 4.89 | Previous week high | +29.37% |
| 4.51 | Previous month low | +19.31% |
| 4.35 | R3 (classic) | +15.17% |
| 4.23 | R2 (classic) | +11.82% |
| 4.10 | Previous day high | +8.47% |
| 4.00 | R1 (classic) | +5.91% |
| 3.88 | Pivot | +2.56% |
| 3.78 | Price now | |
| 3.75 | Previous day low | −0.79% |
| 3.75 | Previous week low | −0.79% |
| 3.65 | S1 (classic) | −3.35% |
| 3.53 | S2 (classic) | −6.70% |
| 3.30 | S3 (classic) | −12.61% |
| 2.93 | 52-week low | −22.49% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.7M | 0.00% | 416.25K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AQST trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.82 per share. | 25K | $120.49K |
| Sep 8, 2026 | Boyd Peter EOfficer | Conversion of Exercise of derivative security at price 0.96 per share. | 2.3K | $2.20K |
| Sep 8, 2026 | Korczynski SherryOfficer | Conversion of Exercise of derivative security at price 2.65 per share. | 8.8K | $23.19K |
| Sep 8, 2026 | Korczynski SherryOfficer | Sale at price 5.22 per share. | 8.8K | $45.67K |
| Sep 7, 2026 | Barber Daniel RChief Executive Officer | Conversion of Exercise of derivative security at price 0.96 per share. | 91.7K | $88.07K |
| Sep 2, 2026 | Jung CassieChief Operating Officer | Conversion of Exercise of derivative security at price 0.96 per share. | 4.6K | $4.40K |
| Aug 16, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.29 per share. | 25K | $107.17K |
| Jul 15, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.00 - 4.03 per share. | 25K | $100.19K |
| Jun 22, 2026 | Krop JulieDirector | Conversion of Exercise of derivative security at price 0.71 per share. | 25K | $17.83K |
| Jun 22, 2026 | Krop JulieDirector | Sale at price 5.02 per share. | 25K | $125.39K |
| Jun 14, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.16 per share. | 25K | $104.01K |
| May 17, 2026 | Zalewski Thomas A.Officer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| May 14, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.29 per share. | 8.3K | $35.41K |
| Mar 9, 2026 | Toth A Ernest JrChief Financial Officer | Sale at price 4.17 per share. | 58.3K | $243.09K |
| Mar 9, 2026 | Barber Daniel RChief Executive Officer | Sale at price 4.17 per share. | 180.7K | $753.97K |
| Mar 9, 2026 | Boyd Peter EOfficer | Sale at price 4.17 per share. | 29.8K | $124.41K |
| Mar 9, 2026 | Braender Lori JOfficer | Sale at price 4.17 per share. | 40.1K | $167.35K |
| Mar 9, 2026 | Jung CassieChief Operating Officer | Sale at price 4.17 per share. | 45.8K | $191.09K |
| Mar 9, 2026 | Korczynski SherryOfficer | Sale at price 4.17 per share. | 15.7K | $65.69K |
| Mar 9, 2026 | Cioffi MelinaOfficer | Sale at price 4.17 per share. | 25.3K | $105.62K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -54.3 | 35.6 | 3.8 | -1.2 | -2.0 | 3.5 | -11.2 | 38.3 | -9.4 | -18.4 | −41.5% | ||
| 2025 | -15.2 | -7.3 | 3.6 | 0.9 | -7.4 | 22.1 | 16.0 | -1.8 | 48.3 | 22.0 | -9.2 | 4.4 | +81.5% |
| 2024 | 18.3 | 53.6 | 16.1 | -21.1 | -14.3 | -9.7 | 47.7 | 18.0 | 9.9 | 10.2 | -7.3 | -30.1 | +76.2% |
| 2023 | -1.3 | -12.0 | 45.6 | 17.5 | 72.4 | -28.6 | 32.7 | -25.1 | -6.7 | 2.6 | 43.3 | -10.2 | +123.9% |
| 2022 | -30.1 | 2.6 | -6.5 | -46.4 | -29.0 | -35.6 | 28.4 | 75.8 | -19.0 | -25.6 | 6.7 | -2.8 | −76.8% |
| 2021 | -1.1 | -13.4 | 13.5 | -21.7 | -8.8 | 7.0 | -18.1 | 40.9 | -4.8 | 17.9 | 14.8 | -34.1 | −27.3% |
| 2020 | -30.4 | -7.9 | -41.3 | 96.8 | 13.0 | -0.2 | 8.2 | 49.4 | -38.2 | -0.3 | 45.9 | -24.2 | −8.1% |
| 2019 | -2.7 | 31.3 | -14.2 | -17.4 | -34.9 | 12.9 | -18.8 | 11.4 | -16.3 | 20.8 | 102.9 | -25.3 | −7.6% |
| 2018 | 19.7 | -2.8 | -13.6 | -43.2 | -26.7 | −58.1% |
TimeframesDown on the hourly, daily and weekly, mixed on the monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Buy / hold / sell counts